Logo
x

Search

Subscribe Now

Arrowhead

Arrowhead Presents New P-II (ARCHES-2) Findings for Zodasiran at AHA 2023

Arrowhead Presents New P-II (ARCHES-2) Findings for Zodasiran at AHA 2023

  • November 14, 2023
Arrowhead Published New Findings from 2 P-II (SHASTA-2 & MUIR) studies for Plozasiran at AHA 2023

Arrowhead Published New Findings from 2 P-II (SHASTA-2 & MUIR) studies for Plozasiran at AHA 2023

  • November 14, 2023
Arrowhead and Janssen Entered into a Licensing Agreement with GSK for JNJ-3989 to Treat Chronic Hepatitis B

Arrowhead and Janssen Entered into a Licensing Agreement with GSK for JNJ-3989 to Treat Chronic Hepatitis B

  • November 1, 2023
Arrowhead Reports the First Patient Dosing of Fazirsiran in the P-III Trial (REDWOOD) for Alpha-1 Antitrypsin Deficiency Associated Liver Disease

Arrowhead Reports the First Patient Dosing of Fazirsiran in the P-III Trial (REDWOOD) for Alpha-1 Antitrypsin Deficiency Associate...

  • April 5, 2023
Arrowhead Gains Full Rights to ARO-PNPLA3 for Patients with Non-Alcoholic Steatohepatitis

Arrowhead Gains Full Rights to ARO-PNPLA3 for Patients with Non-Alcoholic Steatohepatitis

  • February 16, 2023
Arrowhead and Takeda Report P-II Study (SEQUOIA) of Fazirsiran for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Arrowhead and Takeda Report P-II Study (SEQUOIA) of Fazirsiran for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

  • January 10, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.